{
  "study_id": "BNX-451-A",
  "study_name": "BNX-451-A",
  "sponsor": "BioneXus Pharmaceuticals",
  "title": "A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of BNX-451 in Adult Patients with Major Depressive Disorder",
  "phase": "3",
  "indication": "Major Depressive Disorder",
  "therapeutic_area": "Psychiatry",
  "indication_level_quotes": "2456",
  "therapeutic_area_quotes": "8734",
  "population": {
    "age_range": "18 to 65 years",
    "condition": "Major Depressive Disorder",
    "inclusion_highlights": [
      "DSM-5 diagnosis of Major Depressive Disorder",
      "MADRS score ≥ 22",
      "Current major depressive episode ≥ 4 weeks",
      "Inadequate response to prior antidepressant therapy"
    ]
  },
  "design": {
    "randomization": "Yes",
    "control": "Placebo-controlled",
    "blinding": "Double-blind",
    "arms": 3,
    "multicenter": true
  },
  "total_visits": 10,
  "visit_schedule_json": "bnx_451_a_visit_schedule.json"
} 